A phase 1, open-label, dose-escalating study to evaluate the safety, tolerability and immunogenicity of the recombinant plague vaccine rF1V in healthy volunteers.

Trial Profile

A phase 1, open-label, dose-escalating study to evaluate the safety, tolerability and immunogenicity of the recombinant plague vaccine rF1V in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2011

At a glance

  • Drugs Yersinia pestis vaccine (Primary)
  • Indications Plague
  • Focus Adverse reactions
  • Sponsors DynPort Vaccine Company
  • Most Recent Events

    • 29 Jun 2011 Last checked against ClinicalTrials.gov record.
    • 25 Sep 2008 Status changed from active, no longer recruiting to completed.
    • 17 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top